精准肝切除术联合经导管动脉栓塞化疗治疗原发性肝癌的疗效分析

Efficacy analysis of precise hepatectomy combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer

目的探讨精准肝切除术联合经导管动脉栓塞化疗治疗原发性肝癌的疗效。方法将152例原发性肝癌患者根据治疗方法的不同分为联合组(n=80,精准肝切除术联合经导管动脉栓塞化疗)和对照组(n=72,精准肝切除术)。比较两组患者血清肿瘤标志物、肝功能指标、远期生存率以及术后并发症发生情况。结果治疗后,两组患者甲胎蛋白、癌胚抗原水平均下降,且联合组患者甲胎蛋白、癌胚抗原水平均低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者谷草转氨酶、谷丙转氨酶水平均较治疗前下降,差异均有统计学意义(P﹤0.05)。两组患者1、3、5年生存率及并发症总发生率比较,差异均无统计学意义(P﹥0.05)。结论精准肝切除术后联合经导管动脉栓塞化疗治疗原发性肝癌,可有效降低血清肿瘤标志物水平,且对肝功能、远期生存影响较小,临床可考虑将其推广应用。

Objective To investigate the efficacy of precise hepatectomy combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer.Method A total of 152 patients with primary liver cancer were divided into the combined group(n=80,precise hepatectomy combined with transcatheter arterial chemoembolization)and the control group(n=72,precise hepatectomy)according to different treatment methods.Serum tumor markers,liver function indicators,long-term survival rate,and postoperative complications were compared between the two groups.Result After the treatment,the levels of α-fetal protein and carcinoembryonic antigen in the two groups decreased,and the indexes levels in the combined group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of glutamic-oxaloacetic transaminase and glutamic-pyruvic transaminase in the two groups were lower than those before the treatment,and the differences were statistically significant(P<0.05).There were no significant differences in the 1-,3-,and 5-year survival rates and the total incidence of complications between the two groups(P>0.05).Conclusion Precise hepatectomy combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer could effectively reduce serum tumor marker levels and has little effect on liver function and long-term survival.It could be considered for widespread clinical application.